One of the foremost experts in the field of multiple myeloma, Jesus San Miguel, explained in IDIBELL seminar series on 13 April, the approach to this disease that makes his research group at the University Hospital of Salamanca.

The researcher explained that one objective is to understand the pathogenesis of the disease: “We want to know what factors lead to a benign lesion, the MGUS (monoclonal gammopathy of undetermined significance), it becomes a myeloma.”

Improved treatment is another basic objective of the group of Jesus San Miguel, and does so from several approaches: Improving monitoring of patients, be able to intervene at an earlier time, struggle against the acquisition of drug resistance and development of new drugs or new drug combinations.

Currently there is an ongoing international clinical trial with 700 patients to test early treatment in high-risk myeloma quiescent “what we call pre-myeloma, which currently is not treated, and that could improve survival of patients.”